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ABSTRACT 
The disease Diabetes or Madhumeha is well documented in all perennial sources of Ayurvedic 
wisdom. The present study was done to evaluate the efficacy of Bimbi (Coccinia indica) in the 
patients of Diabetes mellitus type-2 through single blind study. Total 30 patients were selected 
and divided into two groups, 15 patients in each group i.e., A (Bimbi) & B (Barley). In this study it 
has been found that Madhumeha affects not only in elderly people but in adults too with slight 
female preponderance. The present study confirmed that after the treatment of 60 days, Bimbi 
(Coccinia indica) was found effective in treatment of Madhumeha and reduced majority of the 
symptoms of illness that including Prabootha mootrata (Excessive urination), Atitrushna 
(Excessive thirst), Avila mootrata (Turbid urine) and Dourbalya (Weakness). There was 
significant improvement in all the laboratory parameters in patients of Bimbi (Coccinia indica) 
treated group. The outcome showed that mean reduction in fasting blood sugar level was 19.86%, 
in PP blood sugar level was 24.52% and in HbA1c level was 8.4%.These outcomes suggest that 
the results of trial drug i.e., Coccinia indica (Bimbi) powder was highly significant at p-value 
<0.001. The drug Bimbi showed effectiveness in reducing FBS, PPBS and HbA1c, as results were 
highly significant. Barley powder used as placebo didn't showed reduction in FBS, PPBS and 
HbA1c. 
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INTRODUCTION 
The recent reports of International Diabetes 
Federation (IDF) shows that, all over the world there 
are 415 million people suffering from diabetes 
mellitus, between the age of twenty to seventy nine 
years, with 8.8% of global prevalence, and it is 
expected that by 2040 it will grow up to 642 million, 
with a prevalence of 10.4%. Environmental 
conditions also play significant role, most of the 
sufferer live in the urban area, and very less come 
from the rural area.[1] 
Many drugs are available in the market to 
control diabetes. In most instances these are 
expensive and may also have adverse effects like 
hypoglycemia and obesity. Ayurveda has mentioned 
many plants useful for pre-diabetes and diabetes 
condition like Berberis aristata, Pterocarpus 
marsupium, Tinospora cordifolia, Azadirachta indica, 
Trichosanthes dioica and Trigonellafoenum graecum.  
Bimbi is botanically identified as Coccinia indica, 
belongs to Cucurbitaceae family.[2] Bimbi is 
mentioned in various Samhitas and Nighantus and 
has been used for treating various disease conditions.  
As per Ayurvedic pharmacopoeia of India[3] Bimbi is 
having Tikta, Madhura-Rasa, Guru, Ruksa-Guna, Sita-
Virya, & Katu-Vipaka. In reference of diabetes, it was 
first mentioned by Acharya Bhavaprakash[4] as 
Mutra-sangrahaniya and described beneficial in 
Madhumeha. Acharya Priyavrata Sharma[5] in 
Dravyaguna vigyan mentioned its effect on 
Mutravaha-sansthana, especially beneficial in 
Madhumeha, Ojomeha & Puyameha.   
Aim & Objective  
To evaluate therapeutic efficacy of Coccinia 
indica (Bimbi) in Madhumeha (type 2 diabetes 
mellitus). 
Material and methods 
Study was approved by the research 
development committee (RDC) of Uttrakhand 
Ayurved University, Harrawala, Dehradun and 
clinical study also approved by Institional Ethical 
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Committee (IEC), Uttaranchal Ayurvedic Collage on 
11 May 2019. 
The clinical trial was also registered in CTRI, 
Govt. of India on 17 July 2019 with reference no. 
REF/2019/07/026977 and trial registration number 
CTRI/2019/07/020228. The study was commenced 
thereafter.  
Source of the drug: The plant material was 
purchased from Rudrapur, Uttrakhand and 
authenticated (with ref.no.–NISCAIR/RHMD/ 
consult/ 2018/3219-20) by Dr. Sunita Garg 
(Emeritus Scientist, CSIR-NISCAIR, New Delhi). The 
authenticated sample i.e., Coccinia indica, Bimbi 
leaves were powdered and passed through the sieve 
no.14 and stored in an air tight container for further 
studies. 
Preparation of the drug for clinical trial: Bimbi 
powder and Barley powder was made under hygenic 
condition. 
Dosage: 6 gm of Bimbi powder twice daily to be 
taken with water, 30 minutes before food, by the 
patients of group-A. 6 gm of Barley powder twice 
daily to be taken with water, 30 minutes before food, 
by the patients of group-B i.e. placebo group. 
Source of the patients: A free medical camp was 
organised in the premises of Uttaranchal Ayurvedic 
hospital, Rajpur road, Dehradun, dated on November 
2, 2019 and again rescheduled on November 12, 
2019. During this period, many patients were 
enrolled while more patients enrolled themselves 
from November 2019 to January 2020. A total of 41 
patients were selected randomly for the study 
irrespective of sex, caste, race and religion. Out of 41 
patients, 11 couldn’t complete the study. 
Study design: 30 selected patients were divided into 
two groups, 15 patients in each group i.e A & B. 
Group A-(Trial group of 15 patients) A pack of 180 
gms was given to each patient of trial group A on 
visit-1 (day-0) and visit-2 (day-15). Further on visit-3 
(day-30) two packets each of 180 gms Bimbi powder 
were given (for next 30 days). 
Groups B- (Placebo group of 15 patients) A pack of 
180 gms of Barley flour was given on visit-1 (day-0) 
and visit-2 (day-15) to every patient enrolled in this 
group. On visit-3 (day-30) two packets each of 180 
gms were given (for next 30 days intake). 
Type of study: Single blind study 
Number of patients: Total 30 Patients completed 
the study. 
Duration of treatment: Total duration of treatment 
was 60 days 
Follow up: Patients were advised to visit for follow-
up on day 0, 15th, 30th, & 60th for testing of the 
objective parameters and to ascertain the adverse 
effects of the treatment if any. 
Inclusion criteria 
 Patients presenting with or without symptoms like 
polyuria, excessive thirst, turbid urine and 
weakness. 
 Patients of either sex between the age group of 30 
to 60 years. 
 Patients of type 2 diabetes mellitus with the FBS 
ranging between 120 mg per dl to 180 mg per dl 
and PPBS ranging between 160 mg per dl to 300 
mg per dl. 
 Established cases of type 2 diabetes mellitus 
without complications. 
Exclusion criteria 
 Juvenile diabetes mellitus. 
 Patients below the age of 30 years and above the 
age of 60 years. 
 Patients suffering from diabetes mellitus due to 
secondary causes, pregnancy and other systemic 
disorders which interferes with course of 
treatment. 
Assessment 
Subjective parameters 
The subjective parameters include for the assessment 
criteria are as below- 
 Excessive urination (Prabootha mootrata) 
 Turbid urine (Avila mootrata) 
  Excessive thirst (Atitrushna)  
 Weakness (Dourbalya)  
Scoring has given to all the signs and symptoms from 
grade 0-3 according to the severity and has 
documented properly before the treatment, after 15 
days, 30 days and 60 days of the treatment. 
Prabootha mootrata (polyuria or excessive 
urination): quantity of urine  
1.50 to 2.00 liters/24 hrs.  : 0 
>2.00 to 2.50 liters /24 hrs. : 1 
>2.50 to 3.00 liters / 24 hrs. : 2 
>3.00 liters / 24 hrs.   : 3 
Frequency of urine  
3-5 times per day, no or rarely at night : 0 
6 - 8 times per day, 1-2 times per night : 1 
9-11 times per day, 3-4 times per night : 2 
>11 times per day, > 4 times per night : 3 
Atitrushna (polydipsia or excessive thirst) 
Feeling of thirst 7-9 times/24 hr, 
either/or intake of water 5-7 times/24 hr 
with quantity  
: 0 
Feeling of thirst 9 - 11 times/24 hr, either : 1 
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/or intake of water 7 - 9 times/24 hr with 
quantity 2.0 - 2.50 liter/24 hr  
Feeling of thirst 11-13 times/24 hr, either 
/or intake of water 9-11 times/24 hr with 
quantity 2.50 -3.00 liter/24 hr  
: 2 
Feeling of thirst >13 times/24 hr, either/ 
or intake of water >11 times/24 hours 
with quantity >3.00 liter/24 hr  
: 3 
Avila mootrata (turbid urine) 
Crystal clear fluid : 0 
Faintly cloudy or hazy with slight turbidity : 1 
Turbidity clearly present and newsprint 
easily read through test tube  
: 2 
Newsprint not easily read through test 
tube 
: 3 
Dourbalya (Weakness) 
Very active : 0 
Active : 1  
Moderate active  : 2  
Dull  : 3  
Objective parameters 
Investigations of blood 
 Fasting blood sugar (FBS) 
 Post-prandial blood sugar (PPBS) 
 HbA1c. 
Urine 
 Fasting urine sugar (FUS) 
 Post prandial urine sugar (PPUS) 
Statistical design 
Statistical analysis was done by paired student “t” 
test. The evaluation was done on the statistical 
analysis of the results obtained (as per American 
Diabetes Association) and it was compared before 
and after treatment. 
Observations  
 The findings of data obtained at the start of 
study have been organized as mentioned below: 
Age wise distribution 
Table 1: Distribution of patients according to age 
Age in year Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
20-30 - 1 1 3.4 
31-40 2 4 6 20.0 
41-50 7 9 16 53.3 
51-60 6 1 7 23.3 
Total 15 15 30 100 
Sex wise distribution 
Table 2: Distribution of patients according to sex 
Sex Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Male 5 9 14 46.7 
Female 10 6 16 53.3 
Total 15 15 30 100 
Marital status wise distribution 
Table 3: Distribution of patients according to Marital status 
Marital status Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Married 15 15 30 100 
Un-married - - 0 0 
Total 15 15 30 100 
Habitat wise distribution 
Table 4: Distribution of patients according to Habitat status 
Habitat status Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Rural 4 5 9 30 
Urban 11 10 21 70 
Total 15 15 30 100 
Family history wise distribution 
Table 5: Distribution of patients according to Family history 
Family History Group-A (Bimbi) Group-B (Barley) No. of Patients Percentage (%) 
Positive 8 5 13 43.3 
Negative 7 10 17 56.7 
Total 15 15 30 30 
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Weight wise distribution 
Table 6: Distribution of patients according to Weight in Kg 
Weight in kgs Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
50-60 2 2 4 13.3 
61-70 5 4 9 30.0 
71-80 5 6 11 36.7 
81-90 3 2 5 16.7 
91-100 - 1 1 3.3 
Total 15 15 30 100 
Educational Status wise distribution 
Table 7: Distribution of patients according to Educational status 
Education  Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Graduates 4 7 11 36.7 
Intermediate 7 7 14 46.6 
Uneducated 4 1 5 16.7 
Total 15 15 30 100 
Occupation wise distribution 
Table 8: Distribution of patients according to Occupational status 
Occupation Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Service  4 6 10 33.3 
Businessman 2 3 5 16.7 
Housewife 7 6 13 43.3 
Retired 2 0 2 6.7 
Total 15 15 30 100 
Socio-economical status wise distribution   
Table 9: Distribution of patients according to Socio-economical status 
Socio-economical 
Status 
Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Poor 4 5 9 30.0 
Lower Middle Class 5 3 8 26.7 
Upper Middle Class 6 7 13 43.3 
Total 15 15 30 100 
Addiction wise distribution 
Table 10: Distribution of patients according to Addiction 
Addiction Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Alcoholics - 2 2 6.7 
Smoking 2 3 5 16.7 
Alcohol+Smoking 1 3 4 13.3 
Alcohol+Smoking &Tobacco 2 2 4 13.3 
No Addiction 10 5 15 50 
Total 15 15 30 100 
Duration of illness wise distribution 
Table 11: Distribution of patients according to Duration of illness 
Duration of Illness Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
0-5 Years 4 3 7 23.4 
5-10 Years 4 6 10 33.3 
>10 Years 7 6 13 43.3 
Total 15 15 30 100 
Mohd Junaid et al. Anti-Hyperglycemic effect of Kundru (Coccinia Indica) on Patients of Diabetes mellitus type-2  
     IJAPR | November 2020 | Vol 8 | Issue 11  33 
Dietary habits (Ahara) wise distribution 
Table 12: Distribution of patients according to Ahara 
Diet Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Veg. 9 5 14 46.7 
Mixed 6 10 16 53.3 
Total 15 15 30 100 
Sleep pattern (Nidra) wise distribution 
Table 13: Distribution of patients based on Nidra 
Nidra Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Sound 2 2 4 13.3 
Moderate 9 6 15 50.0 
Disturbed 4 7 11 36.6 
Total 15 15 30 100 
Symptoms wise distribution 
Table 14: Distribution of patients based on Symptoms 
Symptoms Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
Excessive urination 
(Prabootha ootrata) 
15 15 30 100 
Excessive thirst 
(Atitrushna) 
15 15 30 100 
Turbid urine (Avila 
mootrata) 
14 15 29 96.6 
Weakness (Dourbalya)  12 9 21 70.0 
Fasting Blood Sugar (Day-0) wise distribution 
Table 15: Distribution of patients according to fasting blood sugar (Day-0) 
FBS (mg%) Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
<200 8 7 15 50.0 
200-250 3 3 6 20.0 
250-300 3 1 4 13.3 
>300 1 4 5 16.7 
Total 15 15 30 100 
Post-Prandial blood Sugar (Day-0) wise distribution: 
Table 16: Distribution of patients according to Post-prandial blood sugar (Day-0) 
PPBS (mg%) Group-A (Bimbi) Group-B (Barley) No. of Patients Percentage (%) 
<200 5 3 8 26.6 
200-250 3 3 6 20.0 
250-300 4 3 7 23.3 
>300 3 6 9 30.0 
Total 15 15 30 100 
Glycosylated haemoglobin (Day-0) wise distribution 
Table 17: Distribution of patients according to HbA1c ( Day-0) 
HbA1c Group-A (Bimbi) Group-B (Barley) No. of patients Percentage (%) 
<7 2 2 4 13.3 
7-8 3 5 8 26.7 
8-9 4 3 7 23.3 
>9 6 5 11 36.7 
Total 15 15 30 100 
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Results of Clinical Study 
The patients were analyzed statistically and results obtained were mentioned below: 
Table 18: Results of laboratory parameters in group-A (Trial group) 
Lab  
Tests 
Mean 
B.T 
Mean 
A.T 
Mean  
Dif. 
% Mean 
Reduction 
±S.D ±S.E T 
value 
P 
Value 
Result P value 
Summary 
FBS 186.3 149.3 37 19.86 8.23 2.12 6.58 <0.001  H.S. ˟˟˟ 
PPBS 249.9 188.6 61.3 24.52 10.31 2.66 5.90 <0.001  H.S. ˟˟˟ 
HbA1c 8.64 7.91 0.73 8.44 2.84 0.73 8.46 <0.001  H.S. ˟˟˟ 
FUS 0.28 0.17 0.11 39.28 27.35 7.06 3.23 <0.01 S ˟˟ 
PPUS 0.36 0.20 0.16 44.44 38.56 9.95 5.53 <0.001 H.S ˟˟˟ 
Table 19: Results of laboratory parameters in group-B (Placebo group) 
Symptoms Mean 
B.T 
Mean 
A.T 
Mea
n Dif. 
% Mean 
Reduction 
±S.D ±S.E T 
value 
P 
value 
Result 
 
P value 
Summary 
FBS 229.4 226.9 2.5 1.09 5.66 1.46 0.87 >0.05 N.S. - 
PPBS 269.9 263.2 6.67 2.48 23.02 5.94 0.96 >0.05 N.S. - 
HbA1c 8.49 8.45 0.04 0.47 1.38 0.35 1.24 >0.05 N.S. - 
FUS 0.36 0.33 0.027 7.5 35.19 9.08 1.46 >0.05 N.S. - 
PPUS 0.38 0.36 0.02 5.26 12.10 3.23 1.46 >0.05 N.S. - 
Table 20: Results of symptomatic parameters in group-A (Bimbi) 
Symptoms Mean 
B.T 
Mean 
A.T 
Mean 
Dif. 
% Mean 
Reduction 
±S.D ±S.E T 
value 
P 
Value 
Result 
 
P value 
Summary 
Excessive urination 
(Prabootha 
Mootrata) 
2.20 1.00 1.20 54.54 26.33 6.79 11.22 <0.001 H.S. ˟˟˟ 
Excessive thirst 
(Atitrushna) 
2.20 1.07 1.13 51.36 26.33 6.79 12.47 <0.001 H.S. ˟˟˟ 
Turbid urine (Avila 
Mootrata) 
1.87 0.87 1.00 53.47 32.65 8.431 10.25 <0.001 H.S. ˟˟˟ 
Weakness 
(Dourbalya) 
1.20 0.33 0.87 72.5 39.94 10.31 6.50 <0.001 H.S. ˟˟˟ 
Table 21: Results of symptomatic parameters in group-B (Barley) 
Symptoms Mean 
B.T 
Mean 
A.T 
Mean  
Dif. 
% 
Mean 
reduction 
±S.D ±S.E T 
value 
P 
value 
Result 
 
P value 
Summary 
Excessive urination 
(Prabootha 
Mootrata) 
2.00 1.86 0.14 7.00 15.00 3.87 1.46 >0.05 N.S. - 
Excessive thirst 
(Atitrushna) 
1.93 1.86 0.07 3.62 8.60 2.22 1.00 >0.05 N.S. - 
Turbid urine (Avila 
Mootrata) 
1.66 1.60 0.06 3.61 12.91 3.33 1.00 >0.05 N.S. - 
Weakness 
(Dourbalya) 
0.73 0.66 0.07 9.58 25.82 6.66 1.00 >0.05 N.S. - 
DISCUSSION  
In group-A (Bimbi) after the treatment of 60 
days, there was significant improvement in all the 
laboratory parameters in patients of this group. The 
outcome showed that mean reduction in fasting 
blood sugar level was 19.86%, in PP blood sugar level 
was 24.52% and in HbA1c level was 8.4%.These 
outcomes suggest that the results of trial drug i.e. 
Coccinia indica (Bimbi) powder was highly significant 
at p-value <0.001.  
Along with the blood parameters, fasting 
urine sugar level also showed significant mean 
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reduction by 39.28% at P-value <0.01 and PP urine 
sugar level showed highly significant mean reduction 
by 44.44% at P-value <0.001.  
There was also a significant improvement in 
all the symptomatic parameters. The mean reduction 
in Prabootha mootrata (Excessive urination) was 
54.54%, in Atitrushna (Excessive thirst) was 51.36%, 
in Avila Mootrata (Turbid urine) % was 53.47% and 
in Dourbalya (Weakness) 72.5%. Thus the 
improvement observed in all symptomatic 
parameters in treated group-A (Bimbi) was highly 
significant statistically at P-value <0.001. 
In group-B after the treatment of 60 days, 
there was no significant improvement in all the 
laboratory parameters and all symptomatic 
parameters were non-significant statistically at P-
value >0.05.  
The overall outcome of the study suggests 
that the Coccinia indica (Bimbi) powder showed 
encouraging results on the patients of Diabetes 
mellitus Type-2. The present study supports to the 
use of Coccinia indica (Bimbi) as anti-diabetic 
medicine, as mentioned in Ayurvedic texts.[6,7] 
The present study showed that there was no 
adverse or undesirable side effect noted in terms of 
clinical prevention or lab investigation post studies. It 
is important to note that Pathya-apathya (Dietary 
advices) plays an important role in the management 
of diabetes mellitus type-2, the patients who followed 
the prescribed diet & lifestyle guidelines diligently 
responded well & took less time to recover. 
 The present study illustrates that the overall 
effect of Coccinia indica (Bimbi), with its Rasa, Guna, 
Veerya, Vipaka & Karma, corrected the metabolism of 
blood sugar, eventually helps reduce the level of 
fasting blood sugar, PP blood sugar, HbA1c level, 
reduces the fasting urine sugar level, & PP urine 
sugar level & also shows significant improvement in 
symptomatic parameters of the diabetic patients.  
CONCLUSION  
The study confirmed that Bimbi was effective 
in treatment of Madhumeha and reduced majority of 
the symptoms of illness that including Prabootha 
mootrata (Excessive urination), Atitrushna (Excessive 
thirst), Avila mootrata (Turbid urine) and Dourbalya 
(Weakness). 
All the patients tolerated medicines very well 
and no side effects were reported by any of the 
patients, suggesting there by that the drugs selected 
for current clinical trial was absolutely safe for 
internal usage along with controlling the levels of 
blood and urine sugar effectively. 
It can be concluded that Bimbi was effective 
in relieving symptoms of diabetes and normalizing 
FBS, PPBS, HbA1c and urine sugar level.  
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